Skip to content
OpenCapital
Get started

Incyte INCY JAKAFI — Total revenues

Other product segments

OPZELURA
$143.02M+20.5%
JAKAVI Royalty Revenues
$105.56M+14.6%
NIKTIMVO
$55.09M+305%
MINJUVI/MONJUVI
$49.23M+66.6%
ZYNYZ
$41.39M+1,276%
OLUMIANT Royalty Revenues
$36.41M+18.2%
ICLUSIG
$35.46M+20.0%
PEMAZYRE
$22.54M+22.3%
Milestone and contract revenues
$17M—
TABRECTA Royalty Revenues
$5.98M-6.7%
Other product royalty revenues
$3.25M+156%

Similar metrics at other companies

Aurinia Pharmaceuticals logo
AUPHJapan — Revenue
$4.8M-23.3%
Organon logo
OGNJada — Revenue
$5M-66.7%
QuidelOrtho Corporation logo
QDELJPAC — Total revenues
$70M+2.8%
Exelixis logo
EXELJapan — Total revenues
$12.7M+129%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Cerence Inc. logo
CRNCJapan — Total revenues
$5.43M-70.7%

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
Net income$303.3M+91.7%
EPS (diluted)$1.47+83.7%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$23.32B+78.0%
Enterprise value$19.89B+77.9%
P/E16.3×+1.2×
P/S4.4×+1.5×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp
FCF margin28.2%+19.7pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0×0.0×
Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's jakafi — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's JAKAFI — total revenues?
Incyte (INCY) reported JAKAFI — total revenues of $757.76M in Q1 2026.
How has Incyte's JAKAFI — total revenues changed year-over-year?
Incyte's JAKAFI — total revenues increased by 6.8% year-over-year, from $709.41M to $757.76M.
What is the long-term trend for Incyte's JAKAFI — total revenues?
Over 4 years (2021 to 2025), Incyte's JAKAFI — total revenues has grown at a 9.7% compound annual growth rate (CAGR), from $2.13B to $3.09B.
What does JAKAFI — total revenues mean?
This metric represents the total gross revenue generated from the sales of a specific pharmaceutical product within a defined market. It reflects the commercial performance and market adoption of the drug before accounting for various gross-to-net adjustments. This is a primary indicator of the product's contribution to the company's overall top-line growth.